Our mission is to build global brands of research supported pharmaceutical and non-pharmaceutical medical cannabis derived health products.
HighBreed BioMed is a Canadian company with a mission of building global brands of research supported pharmaceutical and non-pharmaceutical medical cannabis derived health products. HighBreed BioMed is set to become a global market leader in research and testing of cannabis genetics, formulations and production techniques as they relate to pharmaceutical applications, the development of products and brands for specific health ailments as well as the global sale and distribution of branded health products.
HighBreed BioMed is focused on developing research supported topical and oral cannabis-based treatments of common ailments and medical conditions, including:
Through its Israeli based subsidiary, Pharmabis Genetics, HBI has significant relationships within the technological and academic communities in Israel, a global leader in agriculture and medical marijuana research and innovation.
In Canada, HBI holds a minority interest in Thrive Cannabis, a cultivation license holder in Ontario, Canada with an existing 10,000 sq. ft. facility and plans for substantial expansion. In addition, through its parent company, HighBreed Corp.